Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Intra-Patient Cell-Surface Receptor Normalization Refines TNBC Biomarker Profiling for Precision Oncology.

Created on 19 Nov 2026

Authors

Natasha Hardcastle, Nkhasi Lekena, Chardaé Friedberg, Neelakshi Mungra, Fleury A N Biteghe, Suresh Madheswaran, Maryam Karaan, Grace Mayuni, Dharanidharan Ramamurthy, Susan Cooper, Dirk Lang, Dhiren Govender, Krupa Naran, Stefan Barth

Published in

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. Pages 101121. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

Effective precision medicine requires identifying cell-surface receptors (CSRs) selectively overexpressed on tumor cells relative to patient-matched adjacent non-tumor cells a distinction that tumor-only profiling cannot establish. Here, we report DISCOVER-IF Imaging (DIfferentially and SpeCifically OVerexpressed cEll surface Receptors detected by ImmunoFluorescence Imaging), a platform for semi-quantitative, spatially resolved CSR profiling directly on archived formalin-fixed, paraffin-embedded (FFPE) patient tissue. The approach uses recombinant scFv-SNAP-tag fusion proteins, each conjugated to a single fluorophore at a 1:1 stoichiometry, enabling intensity-based semi-quantification of receptor density and comparison of expression between tumor and adjacent non-tumor tissue from each patient. As proof-of-concept, five CSRs previously implicated in triple-negative breast cancer (TNBC)-aspartate β-hydroxylase (AspH), CD44, chondroitin sulfate proteoglycan 4 (CSPG4), epidermal growth factor receptor (EGFR), and epithelial cell adhesion molecule (EpCAM)-were evaluated by immunofluorescence microscopy in a cohort of 10-18 patient samples. All five receptors showed significant tumor-selective overexpression relative to patient-matched non-tumor tissue, with AspH, EGFR, and CSPG4 showing the greatest differences and EpCAM and CD44 showing smaller but significant differences. Intra-patient normalization of tumor-to-adjacent non-tumor expression revealed substantial inter-patient heterogeneity and distinct receptor-dominance patterns, with AspH showing the most consistent tumor-selective overexpression. Notably, intra-patient normalization resolved significant tumor-selectivity even for the low-abundance receptors EpCAM and CD44, demonstrating the relative sensitivity of the approach. By resolving tumor-selective overexpression at the individual-patient level and integrating into standard histopathology workflows as a complement to conventional immunohistochemistry, DISCOVER-IF Imaging offers a generalizable framework for receptor-based stratification in precision oncology. The platform is positioned for integration with digital pathology and AI-assisted analysis, and for extending molecular characterization to populations underrepresented in current datasets.

PMID:
43051595
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement